Omeprazole. Do the dosage and duration of therapy matter? Review article
Article Sidebar
Main Article Content
Abstract
Proton pump inhibitors (PPI) are the strongest medications used in the treatment of acid-dependent gastroenterology diseases that inhibit the secretion of hydrochloric acid in the stomach. One of the longest used and the best known proton pump inhibitor, since 1988, is omeprazol. The strength of the proton pump inhibitors is different in each patient and is caused by genetic conditions, metabolic differences dependent of cytochrome P450 (CYP) and also dependent on the type of acid inhibitor substance. The standard dose of proton pump inhibitors is dependent on the type of medication and is defined by their relative power, which is measured by time of pH maintain longer than 4 in 24 h. Selecting the appropriate omeprazol dose and duration of its use should be personalized and dependent on the indications of the therapy used.
Article Details
Copyright by Medical Education. All rights reserved.
References
2. Katz PO, Dunbar KB, Schnoll-Sussman FH et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022; 117(1): 27-56.
3. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008; 28: 868-77.
4. Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022; 162: 1334-42.
5. Zerbib F, Bredenoord AJ, Fass R et al. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021; 33(4): e14075.
6. Dąbrowski A. Bezpieczeństwo stosowania inhibitorów pompy protonowej. Med Prakt. 2019; 7-8: 128-30.
7. Miner P Jr, Katz PO, Chen Y et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003; 98(12): 2616-20.
8. Armstrong D, Hungin AP, Kahrilas PJ et al.; International Working Group for the Classification of Oesophagitis (IWGCO). Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements. Aliment Pharmacol Ther. 2025; 61(4): 636-50.
9. Armstrong D. Review article: gastric pH – the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther. 2004; 20(Suppl 5): 19-26.
10. Gyawali CP, Kahrilas PJ, Savarino E et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018; 67(7): 1351-62.
11. Fossmark R, Johnsen G, Johanessen E et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005; 21: 149-54.
12. Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol. 2009; 15(8): 990-5.